ESPECTROMETRÍA DE MASAS Y ANÁLISIS BIOMÉDICO
EMAB
Hospital Universitario Central de Asturias
Oviedo, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (11)
2022
2017
-
Cisplatin resistance in cell models evaluation of metallomic and biological predictive biomarkers to address early therapy failure
Metallomics, Vol. 9, Núm. 5, pp. 564-574
-
The fate of iron nanoparticles used for treatment of iron deficiency in blood using mass-spectrometry based strategies
Microchimica Acta, Vol. 184, Núm. 10, pp. 3673-3680
2016
-
Iron speciation, ferritin concentrations and Fe:ferritin ratios in different malignant breast cancer cell lines: On the search for cancer biomarkers
Metallomics, Vol. 8, Núm. 10, pp. 1090-1096
2013
-
Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictiv
Mutagenesis, Vol. 28, Núm. 1, pp. 39-48
2011
-
Quantitative targeted biomarker assay for glycated haemoglobin by multidimensional LC using mass spectrometric detection
Journal of Proteomics, Vol. 74, Núm. 1, pp. 35-43
2008
-
Simultaneous determination of glycated haemoglobin, a long term biomarker of diabetes mellitus, and total haemoglobin by isotope dilution and HPLC-ICP-MS
Journal of Analytical Atomic Spectrometry
1998
-
Low percentage of aluminoxamine and ferroxamine in uremic serum after desferrioxamine administration
Clinical Chemistry, Vol. 44, Núm. 6, pp. 1262-1268
1997
1993
1990
-
High performance liquid chromatography methods for studying protein binding of aluminium in human serum in the absence and in the presence of desferrioxamine
Clinica Chimica Acta, Vol. 189, Núm. 1, pp. 69-79